Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Incorporation of O-Glycopeptides into FVIII Decreases Its Immunogenicity

Meng-Ni Fan, Matthew Chrzanowski, Amber Vander Kooi, Tangliang Shen, Rodney M. Camire, Xiaohe Cai, Ting-Yen Chao, Junping Zhang, Barbara A. Konkle, Carol H. Miao, Lei Li, Weidong Xiao

Blood (2023) 142 (Supplement 1): 1228.

https://doi.org/10.1182/blood-2023-187093

Published: 2023

Journal Articles

Potential Predictive Biomarkers for the Development and Outcomes of Inhibitors in Hemophilia A Patients

Meng-Ni Fan, Tangliang Shen, Xiaohe Cai, Ting-Yen Chao, Marilyn Manco-Johnson, Weidong Xiao, Barbara A. Konkle, Lei Li, Carol H. Miao

Blood (2023) 142 (Supplement 1): 2621.

https://doi.org/10.1182/blood-2023-187660

Published: 2023

Journal Articles

Comparative Glycosylation Mapping of Recombinant and Plasma-Derived Human Factor VIII Reveals Key Biological Differences

Jingyao Qu, PhD, Cheng Ma, PhD, Carol H. Miao, PhD, Peng George Wang, PhD, Weidong Xiao, PhD

Blood (2017) 130 (Supplement 1): 3657.

https://doi.org/10.1182/blood.V130.Suppl_1.3657.3657

Published: 2017

Journal Articles

Ultrasound Combined with Microbubbles Mediated Factor VIII Plasmid Gene Therapy in Hemophilia a Mice

Shuxian Song, PhD, James Harrang, Bryn Smith, Carol H. Miao, PhD

Blood (2015) 126 (23): 2039.

https://doi.org/10.1182/blood.V126.23.2039.2039

Published: 2015

Journal Articles

Effective Therapy for Murine Hemophilia A by Enhancing Factor VIII Expression in Platelets

Xuefeng Wang, PhD, Fu Richard, Carol H. Miao, PhD

Blood (2015) 126 (23): 5547.

https://doi.org/10.1182/blood.V126.23.5547.5547

Published: 2015

Journal Articles

Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells

Cathy X. Wang, Blythe D. Sather, Xuefeng Wang, Jennifer Adair, Iram Khan, Swati Singh, Shanshan Lang, Amie Adams, Gabrielle Curinga, Hans-Peter Kiem, Carol H. Miao, David J. Rawlings, Bruce E. Torbett

Blood (2014) 124 (6): 913–923.

https://doi.org/10.1182/blood-2013-12-546218

Published: 2014

Includes: Supplemental data

Journal Articles

Murine Hemophilia A With Or Without Pre-Existing Anti-Factor VIII Inhibitors Is Partially Corrected By Factor VIII Stored In Platelets After Intraosseous Infusion Of Lentiviral Vectors Into Bone Marrow Without Preconditioning

Xuefeng Wang, PhD, Simon C. Shin, Chiang Andy, Dao Pan, PhD, David Rawlings, MD, Carol H. Miao, PhD

Blood (2013) 122 (21): 719.

https://doi.org/10.1182/blood.V122.21.719.719

Published: 2013

Journal Articles

Targeting Long-Lived Plasma Cells Is Essential For Treating Hemophilia A Inhibitors

Chao Lien Liu, Ph.D, Meghan Lyle, B.S., Simon Shin, B.S., Carol H. Miao, PhD

Blood (2013) 122 (21): 927.

https://doi.org/10.1182/blood.V122.21.927.927

Published: 2013

Journal Articles

Progress toward inducing immunologic tolerance to factor VIII

David W. Scott, Kathleen P. Pratt, Carol H. Miao

Blood (2013) 121 (22): 4449–4456.

https://doi.org/10.1182/blood-2013-01-478669

Published: 2013

Journal Articles

Cell therapy for hemophilia

Carol H. Miao

Blood (2012) 119 (23): 5344–5346.

https://doi.org/10.1182/blood-2012-04-415042

Published: 2012

Journal Articles

Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome

Alexander Astrakhan, Blythe D. Sather, Byoung Y. Ryu, Socheath Khim, Swati Singh, Stephanie Humblet-Baron, Hans D. Ochs, Carol H. Miao, David J. Rawlings

Blood (2012) 119 (19): 4395–4407.

https://doi.org/10.1182/blood-2011-03-340711

Published: 2012

Includes: Supplemental data

Journal Articles

In Vivo Expansion of Treg Cells Prevents Anti-FVIII Antibody Production Following FVIII Protein Replacement Therapy in Hemophilia A Mice

Chao-Lien Liu, Peiqing Ye, Jaqueline Lin, Carol H. Miao, PhD

Blood (2011) 118 (21): 23.

https://doi.org/10.1182/blood.V118.21.23.23

Published: 2011

Journal Articles

Development of Direct Intra-Bone Marrow Gene Transfer of Lentiviral Vectors Containing a B-Domain Variant of Human Factor VIII for Hemophilia A Treatment

Xuefeng Wang, Liping Chen, Peiqing Ye, Andy Chiang, Carol H. Miao, PhD

Blood (2011) 118 (21): 4710.

https://doi.org/10.1182/blood.V118.21.4710.4710

Published: 2011

Journal Articles

Anti-CD3 antibodies modulate anti–factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy

Baowei Peng, Peiqing Ye, David J. Rawlings, Hans D. Ochs, Carol H. Miao

Blood (2009) 114 (20): 4373–4382.

https://doi.org/10.1182/blood-2009-05-217315

Published: 2009

Includes: Supplemental data

Journal Articles

CD4 + FOXP3 + regulatory T cells confer long-term regulation of factor VIII–specific immune responses in plasmid-mediated gene therapy–treated hemophilia mice

Carol H. Miao, Benjamin R. Harmeling, Steven F. Ziegler, Benjamin C. Yen, Troy Torgerson, Liping Chen, Roger J. Yau, Baowei Peng, Arthur R. Thompson, Hans D. Ochs, David J. Rawlings

Blood (2009) 114 (19): 4034–4044.

https://doi.org/10.1182/blood-2009-06-228155

Published: 2009

Includes: Supplemental data

Journal Articles

A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3 + T regulatory cells

Hideto Matsui, Masaru Shibata, Brian Brown, Andrea Labelle, Carol Hegadorn, Chandler Andrews, Marinee Chuah, Thierry VandenDriessche, Carol H. Miao, Christine Hough, David Lillicrap

Blood (2009) 114 (3): 677–685.

https://doi.org/10.1182/blood-2009-03-202267

Published: 2009

Journal Articles

Engineered Factor IX with Augmented Clotting Activities in a Hemophilia B Mouse Model.

Chia-Ni Lin, Chung-Yang Kao, Chia-Lun Hong, Peiqing Ye, Carol H. Miao, PhD, Nobuko Hamaguchi, Hua-Lin Wu, Guey-Yueh Shi, Yung-Li Yang, I-Shing Yu, Mi-Hua Tao, Cheng-Chieh Fang, Yi-Lin Liu, Katherine A. High, MD, Shu-Wha Lin

Blood (2008) 112 (11): 2025.

https://doi.org/10.1182/blood.V112.11.2025.2025

Published: 2008

Journal Articles

Reduction of Inhibitory Anti-FVIII Antibody Titer by Using a B Domain Variant FVIII/N6 cDNA for Nonviral Gene Therapy in Hemophilia a Mice

Dominika Jirovska, Peiqing Ye, Steven W. Pipe, MD, Carol H. Miao, PhD

Blood (2008) 112 (11): 3537.

https://doi.org/10.1182/blood.V112.11.3537.3537

Published: 2008

Journal Articles

Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice

Baowei Peng, Peiqing Ye, Bruce R. Blazar, Gordon J. Freeman, David J. Rawlings, Hans D. Ochs, Carol H. Miao

Blood (2008) 112 (5): 1662–1672.

https://doi.org/10.1182/blood-2008-01-128413

Published: 2008

Journal Articles

Transient Blockade of ICOS Co-Stimulatory Pathways Induces Long-Term Tolerance to Factor VIII Following Nonviral Gene Transfer of Factor VIII Plasmid into Hemophilia A Mice.

Baowei Peng, PhD, Peiqing Ye, MD, Bruce R. Blazer, MD, Hans D. Ochs, MD, MSc, Carol H. Miao, PhD

Blood (2006) 108 (11): 3283.

https://doi.org/10.1182/blood.V108.11.3283.3283

Published: 2006

NARROW

Incorporation of O-Glycopeptides into FVIII Decreases Its Immunogenicity

Potential Predictive Biomarkers for the Development and Outcomes of Inhibitors in Hemophilia A Patients

Comparative Glycosylation Mapping of Recombinant and Plasma-Derived Human Factor VIII Reveals Key Biological Differences

Ultrasound Combined with Microbubbles Mediated Factor VIII Plasmid Gene Therapy in Hemophilia a Mice

Effective Therapy for Murine Hemophilia A by Enhancing Factor VIII Expression in Platelets

Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells

Murine Hemophilia A With Or Without Pre-Existing Anti-Factor VIII Inhibitors Is Partially Corrected By Factor VIII Stored In Platelets After Intraosseous Infusion Of Lentiviral Vectors Into Bone Marrow Without Preconditioning

Targeting Long-Lived Plasma Cells Is Essential For Treating Hemophilia A Inhibitors

Progress toward inducing immunologic tolerance to factor VIII

Cell therapy for hemophilia

Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome

In Vivo Expansion of Treg Cells Prevents Anti-FVIII Antibody Production Following FVIII Protein Replacement Therapy in Hemophilia A Mice

Development of Direct Intra-Bone Marrow Gene Transfer of Lentiviral Vectors Containing a B-Domain Variant of Human Factor VIII for Hemophilia A Treatment

Anti-CD3 antibodies modulate anti–factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy

CD4 + FOXP3 + regulatory T cells confer long-term regulation of factor VIII–specific immune responses in plasmid-mediated gene therapy–treated hemophilia mice

A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3 + T regulatory cells

Engineered Factor IX with Augmented Clotting Activities in a Hemophilia B Mouse Model.

Reduction of Inhibitory Anti-FVIII Antibody Titer by Using a B Domain Variant FVIII/N6 cDNA for Nonviral Gene Therapy in Hemophilia a Mice

Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice

Transient Blockade of ICOS Co-Stimulatory Pathways Induces Long-Term Tolerance to Factor VIII Following Nonviral Gene Transfer of Factor VIII Plasmid into Hemophilia A Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only